NovoCure touts long-term analysis for Optune TTF, drug combo in brain cancer

NovoCure (NSDQ:NVCR) today released long-term analysis data from the phase 3 pivotal EF-14 trial of its Optune device in combination with temozolomide for treating newly diagnosed glioblastoma, touting superior survival results. Data from the trial indicated superior 2, 3 and 4-year survival rates for patients treated with the combined therapy over temozolomide alone. Data from the study is slated to be presented at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology in Scottsdale, Ariz. this week. “The long-term analysis further supports our data showing that Optune together with temozolomide is a better treatment option for newly diagnosed GBM patients compared to temozolomide alone. We believe these results will give health care providers further confidence in our therapy and transform the standard of care in newly diagnosed GBM. Our priority is to improve the lives of GBM patients, and we believe these results will help us to accomplish our mission,” CEO Asaf Danziger said in prepared remarks. Patients treated with the combined therapy reported a significant increase in median progression free survival, at 6.7 months versus 4 for those treated with the drug alone. They also reported an increase in median overall survival, at 20.8 months versus 16 months for the drug alone. A total of 43% of patients treated with the combined therapy were alive at 2 years, versus 30% with the drug alone. Seventeen percent lived to 4 years, versus 10% with the ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Oncology NovoCure Source Type: news